Innate Pharma Valuation
| IPH Stock | EUR 1.43 0.10 6.54% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Innate Pharma retains a regular Real Value of €1.62 per share. The prevalent price of the firm is €1.43. Our model calculates the value of Innate Pharma from evaluating the firm fundamentals such as Current Valuation of 86.87 M, return on asset of -0.043, and Return On Equity of -0.17 as well as inspecting its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Innate Pharma's price fluctuation is very risky at this time. Calculation of the real value of Innate Pharma is based on 3 months time horizon. Increasing Innate Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Innate Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Innate Stock. However, Innate Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.43 | Real 1.62 | Hype 1.43 |
The real value of Innate Stock, also known as its intrinsic value, is the underlying worth of Innate Pharma Company, which is reflected in its stock price. It is based on Innate Pharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Innate Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Innate Pharma helps investors to forecast how Innate stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Innate Pharma more accurately as focusing exclusively on Innate Pharma's fundamentals will not take into account other important factors: Innate Pharma Total Value Analysis
Innate Pharma is currently forecasted to have takeover price of 86.87 M with market capitalization of 224.71 M, debt of 46.5 M, and cash on hands of 103.76 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Innate Pharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
86.87 M | 224.71 M | 46.5 M | 103.76 M |
Innate Pharma Investor Information
About 23.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.43. Some equities with similar Price to Book (P/B) outperform the market in the long run. Innate Pharma has Price/Earnings (P/E) ratio of 125.2. The entity recorded a loss per share of 0.27. The firm had not issued any dividends in recent years. Based on the key measurements obtained from Innate Pharma's financial statements, Innate Pharma is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Innate Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Innate Pharma has an asset utilization ratio of 4.53 percent. This suggests that the Company is making €0.0453 for each dollar of assets. An increasing asset utilization means that Innate Pharma is more efficient with each dollar of assets it utilizes for everyday operations.Innate Pharma Ownership Allocation
Innate Pharma has a total of 80.2 Million outstanding shares. Innate Pharma secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Innate Pharma Profitability Analysis
The company reported the revenue of 12.11 M. Net Loss for the year was (52.81 M) with loss before overhead, payroll, taxes, and interest of (22.3 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Innate Pharma's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Innate Pharma and how it compares across the competition.
About Innate Pharma Valuation
The stock valuation mechanism determines Innate Pharma's current worth on a weekly basis. Our valuation model uses a comparative analysis of Innate Pharma. We calculate exposure to Innate Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Innate Pharma's related companies.Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. The company was founded in 1999 and is based in Marseille, France. INNATE PHARMA operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 191 people.
8 Steps to conduct Innate Pharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Innate Pharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Innate Pharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Innate Pharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Innate Pharma's revenue streams: Identify Innate Pharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Innate Pharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Innate Pharma's growth potential: Evaluate Innate Pharma's management, business model, and growth potential.
- Determine Innate Pharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Innate Pharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Innate Stock analysis
When running Innate Pharma's price analysis, check to measure Innate Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innate Pharma is operating at the current time. Most of Innate Pharma's value examination focuses on studying past and present price action to predict the probability of Innate Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innate Pharma's price. Additionally, you may evaluate how the addition of Innate Pharma to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |